creating the ideal immunotherapy
The ideal immunotherapy should have three characteristics - highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. 

By developing products exclusively directed to cancer cells carrying a transgene coding for one or more antitumour or immune activator drugs, Trocept is the first approach that meets these three requirements.

Watch the animation below to see how Trocept works. 
Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. 

As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. 

Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

The first drug candidate generated by the Trocept platform is expected to be IND stage by late 2023. 
harnessing the immune system to tackle tumour cell diversity
engineered for cancer specificity and to carry transgene
enters cancer cells and replicates
Cancer cell breakdown generates strong localised immune response
Transgene expression of immune activators or antitumour drugs
Potent local immune response eradicates all cancer cell variants with minimum toxicity
trocept pipeline